The Lawyer's Eye — Can This Material Survive Cross-Examination?

In material review, you often hear: "we only stated facts." A lawyer doesn't accept that framing. A lawyer questions the act of selection itself — what was shown, what was withheld, why, and who decided. Cross-examination is the systematic technique for dismantling exactly that. When a reviewer adopts this mindset, explanations that hide behind "technically accurate" begin to crack at the seams.

So What / So Why — The Core of This Lens

The core point, stated plainly: the problem with promotional materials lives not in what is written, but in what is not. Courtroom cross-examination is the work of breaking down testimony from the inside. The lawyer does not ask "Is this true?" The lawyer asks: "Why didn't you use the other data?" "What did the deleted section say?" "Who made that call?" Bring those questions into material review and you find, inside a polished document, the residue of choices that cannot be explained after the fact.

Why does this lens matter? When the Ministry of Health, Labour and Welfare developed its guidelines in response to the review council that began in 2017, the underlying recognition was that "conduct that leaves little evidence — such as verbal explanations — and conduct that, while not clearly false or exaggerated, is considered likely to encourage inappropriate use" (MHLW Promotional Activities Monitoring Report, 2020) had been repeated. The regulator itself identified the cumulative effect of gray-zone omissions and selective presentation as the problem. That gaze is structurally identical to the one an adversarial third party — litigation counsel, inspector, journalist — brings when they pick up your material.

When reviewers develop the habit of cross-examining their own materials, problems can be stopped before release. This lens is not merely legal risk management. It is another name for the work of protecting the quality of information that reaches clinicians.

Inside the Lens — What, Where, Why, How

What (what does this lens look for in a material)
It looks at the gap between the data cited and its source. Is any arm missing from the graph? Did any adverse event disappear from the listing? Are the primary and secondary endpoints treated with equal weight? Does the title or headline hold up against what the underlying data actually show? A lawyer calls this "intentional omission." A reviewer may claim they simply didn't notice — but a lawyer doubts that claim too.

Where (where do problems tend to hide)
The most overlooked area is the design of graphs and the proportion of space allocated to each section. Covering the primary endpoint in three lines of text while devoting two pages of graphs to a secondary endpoint is not a lie. But when a lawyer asks "why is there no comparative graph for the primary endpoint?", the answer stalls. Similarly, when an arm that exists in the source publication has disappeared from the material, "space constraints" is a fragile answer under cross-examination.

Why (why does review need this lens)
Material authors have a natural motivation to present their product favorably. That is not inherently wrong. The problem arises when that motivation accumulates as a series of locally justifiable choices that, viewed together, create a one-directional impression. Each individual choice — "clinicians want this," "space is limited" — may be defensible in isolation. Seen as a bundle from the outside, the intent becomes readable. The lawyer's eye reads the bundle.

How (how to frame the questions in practice)
Four questions that work in a review session: (1) What other data exist in the source publication or regulatory review report? (2) What data were not included, and can you explain why? (3) How will the primary endpoint result land with a clinician reading this material? (4) If this choice were flagged in a monitoring report three years from now, could you defend it? These are standard cross-examination patterns. When reviewers direct them at themselves, materials move from "technically correct" to "accountable."

Stepping Into the Role — What You See From That Chair

Imagine you are plaintiff's counsel, and you have just been handed a promotional brochure. Your client received a specific antiviral drug for treatment of a viral infection. The prescribing physician explained that "this drug is highly effective at reducing viral load." The basis for that claim was a pamphlet brought by the MR. Your client recovered, but the treating physician later noticed something: the pamphlet gave the primary endpoint three lines of text and no comparative graph, while spending two full pages detailing secondary endpoints with charts comparing the study drug to the control. The primary endpoint showed no statistically significant difference from the control.

You call the company's review officer to the stand. "Why is there no comparative graph for the primary endpoint?" The answer will be "space constraints." "You devoted two pages to the secondary endpoints but could not fit a single graph for the primary endpoint?" A silence forms. Something could have stopped this before that silence was possible.

You can also inhabit the inspector's position. The phrase "conduct that leaves little evidence" recurs in the regulator's reports precisely because verbal explanations and selective graph presentations do not generate paper trails. That is why the material itself becomes the record. Whether that record holds up under adversarial questioning answers two things at once: whether the process was honest, and whether the organization is exposed.

Reading Past Failures Through This Lens

The 2019 MHLW Promotional Activities Monitoring Report (document 000509783) contains two cases where the lawyer's eye cuts sharpest.

Case 1: Antiviral drug / product introduction pamphlet (②-9)

A pamphlet focused on "viral reduction effect" introduced the primary endpoint result (duration of illness) in "only a few lines of text, with no comparative result against the control drug shown." The secondary endpoints — "change in viral titer" and "time to cessation of viral shedding" — were detailed across two pages with graphs comparing the study drug to the control. The report recorded:

"There was no statistically significant difference from the control drug on the primary endpoint, and arbitrariness was observed in how the data were presented."

The cross-examination runs like this: "Did the physicians who read this pamphlet know there was no significant difference on the primary endpoint?" The answer is no. "Did your company know?" Yes. Two questions, and the structure of accountability collapses. If the reviewer had asked those questions first, the pamphlet's layout would have changed. Anatomy of Failures, Vol. 2: Selective Extraction, Manipulation, and Framing of Data and Graphs organizes this case alongside more than 24 others by year.

Case 2: Bronchial asthma treatment / in-hospital product presentation slides and pamphlet (②-13)

For the primary endpoint of a Phase III international joint trial (annual asthma exacerbation rate), the full analysis (approximately 250 patients per arm) was not presented. Only a subgroup analysis of the Japanese population (approximately 15 patients per arm) was shown. When the responsible person was asked why, the response was:

"Because physicians want Japanese data."

In cross-examination, that statement is self-defeating. "Were the Japanese subgroup results better than the full analysis results?" Yes. "So you deliberately selected and presented the data that clinicians would respond most favorably to?" The denial follows, but the report has already recorded "arbitrariness was perceived." The written record becomes the evidence. If the reviewer had first asked "why aren't we using the full analysis?", that answer could have been closed off.

In both cases, nothing was false. The secondary endpoints were real data. The Japanese subgroup was a genuine result. The problem is the trace of intent visible when the selection is viewed from outside. The lawyer's eye reads that trace. When reviewers develop the same eye, the material is stopped before it reaches the world.